Endometrial Ablation Devices Market Size and Share
Market Overview
| Study Period | 2020 - 2031 |
|---|---|
| Market Size (2026) | USD 1.26 Billion |
| Market Size (2031) | USD 1.62 Billion |
| Growth Rate (2026 - 2031) | 5.14% CAGR |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. | |
Endometrial Ablation Devices Market Analysis by Mordor Intelligence
The endometrial ablation devices market size was valued at USD 1.20 billion in 2025 and estimated to grow from USD 1.26 billion in 2026 to reach USD 1.62 billion by 2031, at a CAGR of 5.14% during the forecast period (2026-2031). Demand is rising as clinicians replace hysterectomy with less invasive solutions for abnormal uterine bleeding (AUB). Thermal systems remain dominant, but non-thermal technologies are scaling quickly on precision benefits. Regulatory guidance that tightens safety verification, broader reimbursement for office-based care, and investments in single-use platforms collectively shape near-term growth. Competitive focus is shifting to artificial-intelligence (AI) guidance, disposable hysteroscopic instruments, and outpatient-friendly designs that lower total procedure cost.
Key Report Takeaways
- By device technology, thermal platforms led with 55.10% revenue share in 2025, while non-thermal options are advancing at a 9.12% CAGR to 2031.
- By device type, radiofrequency systems accounted for 44.10% of the endometrial ablation devices market share in 2025; balloon ablators are forecast to expand at an 8.05% CAGR through 2031.
- By access approach, hysteroscopic systems held 49.05% of 2025 revenue, yet image-guided extra-uterine procedures are growing fastest at an 11.32% CAGR.
- By end user, hospitals captured 44.30% revenue in 2025, whereas ambulatory surgical centers (ASCs) are climbing at a 10.05% CAGR through 2031.
- By geography, North America dominated with 41.35% of 2025 sales; Asia-Pacific is set to grow at an 8.10% CAGR to 2031.
Note: Market size and forecast figures in this report are generated using Mordor Intelligence’s proprietary estimation framework, updated with the latest available data and insights as of 2026.
Global Endometrial Ablation Devices Market Trends and Insights
Drivers Impact Analysis*
| Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising Prevalence Of Abnormal Uterine Bleeding (AUB) | +1.2% | Global, with higher impact in North America & Europe | Long term (≥ 4 years) |
| Growing Demand For Minimally-Invasive Gynecologic Procedures | +0.8% | Global, accelerated in APAC emerging markets | Medium term (2-4 years) |
| Rapid Outpatient Migration To Ambulatory Surgery Centers | +1.5% | North America & EU core, expanding to APAC | Short term (≤ 2 years) |
| Increasing Reimbursement Coverage For Office-Based Ablation | +0.9% | North America primary, selective EU markets | Medium term (2-4 years) |
| AI-Guided Imaging Improving Procedural Accuracy | +1.1% | North America & EU early adoption, APAC following | Long term (≥ 4 years) |
| Emergence Of Single-Use Hysteroscopic Systems Lowering Infection Risk | + 0.7% | Global, with premium market focus initially | Medium term (2-4 years) |
| Source: Mordor Intelligence | |||
Rising Prevalence of Abnormal Uterine Bleeding (AUB)
AUB affects 14–25% of reproductive-age women, and incidence climbs in the 40–50 age group. Recent findings flag heavy menstrual bleeding as an independent cardiovascular risk factor, pushing clinicians toward definitive therapy earlier in the care pathway[1]Janesh Gupta, “Abnormal Uterine Bleeding – Symptoms, Diagnosis and Treatment,” BMJ Best Practice, bestpractice.bmj.com. Greater awareness widens the treatable population and sustains demand for ablation, enlarging the endometrial ablation devices market.
Growing Demand for Minimally-Invasive Gynecologic Procedures
Enhanced imaging, such as indocyanine-green fluorescence, lowers complication rates, while novel manipulation methods shorten operating time by 25%. Office-based ablation cuts per-patient costs by USD 1,498, making minimally invasive care compelling for payers and providers alike.
Rapid Outpatient Migration to ASCs
Patient satisfaction remains high, with 96% reporting sustained bleeding reduction five years after NovaSure treatment[2]Hologic, “NovaSure Endometrial Ablation,” Hologic, hologic.co.uk. Payers favor ASC procedures that trim facility fees, and device makers have responded with systems optimized for small-footprint settings.
AI-Guided Imaging Improving Procedural Accuracy
Deep-learning algorithms now detect uterine pathologies in ultrasound scans with 99% accuracy, offering intra-procedure guidance that standardizes outcomes and lowers the training barrier for new operators. AI integration differentiates premium offerings in the endometrial ablation devices market.
Restraints Impact Analysis*
| Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Unfavorable Or Heterogeneous Regulatory Pathways | -0.6% | Global, with varying intensity by region | Long term (≥ 4 years) |
| High Capital Cost Of Advanced RF & HIFU Platforms | -0.4% | Emerging markets primary, selective developed markets | Medium term (2-4 years) |
| Shortage Of Trained Hysteroscopists In Emerging Markets | -0.3% | APAC, MEA, Latin America focus | Long term (≥ 4 years) |
| Slow Procedural Adoption Due To Fertility-Preservation Concerns | -0.2% | Global, with cultural variations | Medium term (2-4 years) |
| Source: Mordor Intelligence | |||
Unfavorable or Heterogeneous Regulatory Pathways
Divergent rules extend approval timelines and inflate compliance costs. The FDA’s draft guidance on thermal effects adds premarket data burdens, and India’s evolving framework creates uncertainty for foreign entrants.
High Capital Cost of Advanced RF & HIFU Platforms
Upfront investment for Class III systems can exceed USD 5 million, straining budgets in cost-sensitive regions and delaying adoption until volume scales lower per-procedure expense.
*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.
Segment Analysis
By Device Technology: Thermal Dominance Faces Non-Thermal Disruption
Thermal platforms generated 55.10% of 2025 revenue, confirming their role as the clinical mainstay of the endometrial ablation devices market. Proven safety and surgeon familiarity underpin this lead. Meanwhile, non-thermal modalities are forecast to grow at 9.12% CAGR. Cryoablation is gaining share through expanded European adoption, and MRI-guided focused ultrasound secured five new therapeutic indications in 2024.
Competitive dynamics now hinge on specialty applications where thermal limits arise—for instance, cases requiring ultra-precise tissue sparing. That shift widens the clinical footprint of non-thermal solutions without immediately eroding thermal revenue streams.
By Device Type: RF Systems Lead While Balloon Technologies Surge
Radiofrequency systems represented 44.10% revenue in 2025, and their broad utility keeps them central to procedure volumes. Balloon ablators, however, are set for an 8.05% CAGR to 2031 as simplified, single-use models reduce infection risk and learning curve. Hologic’s smart-depth technology and cavity-integrity assessment continue to anchor RF’s popularity, whereas Minerva’s silicone-mesh array illustrates how design differentiation propels balloon adoption.
The endometrial ablation devices market size for balloon technologies is projected to expand at the fastest clip within the device-type hierarchy, emphasising an industry-wide pivot to outpatient-friendly tools.
By Access Approach: Hysteroscopic Dominance Challenged by Image-Guided Innovation
Hysteroscopic systems supplied 49.05% of 2025 sales and remain the visualization gold standard. Yet MRI-guided and ultrasound-guided extra-uterine ablation, regulated as Class III products, is gaining momentum with an 11.32% CAGR. Image-guided offerings promise non-invasive treatment plus granular targeting, appealing to patients preferring no cervical entry.
Transcervical methods sit between these extremes, balancing broader eligibility with modest infrastructure needs. As precision medicine expands, image guidance will likely pull share from legacy platforms, but hysteroscopy’s entrenched install base will preserve meaningful volume through 2031.
By End User: Hospital Dominance Shifts Toward Ambulatory Settings
Hospitals maintained 44.30% of 2025 demand owing to comprehensive support services for complex cases. ASCs, on a 10.05% CAGR path, capture growth by pairing lower facility fees with rapid recovery. Evidence shows office ablation matches hospital safety while saving nearly USD 1,500 per case.
Specialty clinics further broaden access, especially where single-use scopes sidestep reprocessing issues highlighted in ACOG guidance. As these outpatient venues build procedural scale, the endometrial ablation devices market size linked to office settings is expected to rise steadily.
Geography Analysis
North America commanded 41.35% of 2025 revenue, underwritten by comprehensive reimbursement, dense specialist networks, and patient awareness. The endometrial ablation devices market size in the region will advance at mid-single-digit rates as AI guidance and disposable scopes deepen penetration.
Europe remains an innovation center that values evidence-based adoption. Structured procurement favors proven technologies, yet ASC migration in the United Kingdom, France, and Germany should accelerate growth.
Asia-Pacific, advancing at an 8.10% CAGR, benefits from widening insurance coverage, urban middle-class expansion, and government incentives for women’s health. Local manufacturing partnerships in India and export-oriented Chinese players broaden device availability.
Emerging markets in South America, the Middle East, and Africa exhibit early-stage demand. Investments in tertiary hospitals and specialty centers gradually unlock procedure capacity, though economic volatility tempers near-term volume.
Regulatory Landscape
Regulation remains a key gating factor for endometrial ablation systems because many platforms are invasive and energy-based, which typically places them in higher-risk categories and increases evidence requirements. In the United States, the FDA regulates endometrial ablation products under pathways that include 510(k) clearance and PMA depending on technology and labeling, and it also maintains device-specific expectations for thermal endometrial ablation submissions through its IDE-focused guidance, reinforcing premarket testing requirements around thermal effects and safety verification.
In Europe, Regulation (EU) 2017/745 (MDR) continues to shape market access through CE marking requirements, with strengthened clinical evaluation, post-market surveillance, and technical documentation expectations for Class IIb invasive, energy-based devices. Australia is adding traceability obligations, with the Therapeutic Goods Administration (TGA) implementing Unique Device Identification (UDI) requirements effective 1 July 2026 for higher-risk classes (including Class IIb and III), increasing compliance work for manufacturers supplying disposable components and multi-part procedural kits.
Competitive Landscape
The endometrial ablation devices market shows moderate fragmentation. Global leaders leverage broad portfolios, strong clinical data, and after-sales service to shield share. Hologic’s NovaSure platform has treated more than 3 million patients with durable outcomes. Boston Scientific is scaling cryoablation centers across France, evidencing multinational push into non-thermal niches.
Strategic themes include AI overlays that standardize treatment, single-use hysteroscopes that cut reprocessing cost, and platform robotics exemplified by Johnson & Johnson’s IDE-cleared OTTAVA system. Smaller innovators such as Meditrina raise capital to commercialize bipolar RF systems tailored for office workflows, signaling investor confidence in outpatient trends.
Value-oriented entrants from China plan to compete on cost-performance balance, a strategy that could compress pricing in middle-income markets over the forecast period.
Endometrial Ablation Devices Industry Leaders
Olympus Corporation
Boston Scientific Corporation
CooperSurgical, Inc.
Medtronic plc
Johnson & Johnson (Ethicon)
- *Disclaimer: Major Players sorted in no particular order
Market Opportunities and Future Outlook
Outpatient migration is creating whitespace for simplified, small-footprint systems and disposable or single-use hysteroscopic instruments that reduce reprocessing burden and help standardize workflows in ASCs and office-based gynecology practices. The report’s evidence supports this direction, including that office ablation lowers per-patient cost by about USD 1,498 and that ASCs are the fastest-growing end-user channel, which favors platforms built around rapid setup, short cycle times, and predictable care pathways.
Regulatory activity also points to near-term opportunities in manufacturing resilience and component traceability, especially for PMA-controlled systems where supply-chain changes often require formal supplements. The FDA approval of a February 2026 supplier change for injection-molded components used in the Minerva Endometrial Ablation Handpiece (PMA supplement) illustrates how incremental, compliant manufacturing updates can support continuity of supply and scaling single-use consumption without changing clinical labeling. Separately, the 1 July 2026 start of Australia’s UDI requirements for higher-risk classes encourages vendors to strengthen device identification and post-market data infrastructure across global distribution, supporting hospital procurement and multi-site standardization initiatives.
Recent Industry Developments
- May 2026: Boston Scientific announced FDA approval for the next-generation Genesys HTA system. The clearance strengthens Boston Scientific’s position in hydrothermal ablation by refreshing its platform within the US regulatory framework, supporting competitive differentiation in settings that value uterine-cavity treatment control.
- March 2026: IWK Health reported performing the first Cerene cryoablation therapy procedures in Canada following Health Canada approval. This marked early clinical adoption at a major Canadian care provider, expanding real-world utilization in a non-thermal modality and supporting broader provider awareness outside the United States.
- October 2024: Minerva Surgical signed an agreement with Blackmaple Group (BMG) and WHAAPA to expand access and administrative support for its office-based endometrial ablation offering. The partnership targets practice enablement and purchasing workflows, reinforcing the market’s shift toward office and ambulatory settings where streamlined contracting and support can accelerate procedural adoption.
Research Methodology Framework and Report Scope
Market Definition and Coverage
For this study, the market covers revenues from endometrial ablation devices used to destroy or remove the uterine lining to treat abnormal uterine bleeding, across hospital, ambulatory, and office care settings. It includes device systems and their procedure-enabling components sold for endometrial ablation.
Scope exclusions: We exclude general gynecologic electrosurgery tools or energy generators that are not specifically labeled or cleared for endometrial ablation.
Segmentation Overview
- By Device Technology
- Thermal Ablation
- Non-Thermal Ablation
- By Device Type
- Hysteroscopy Devices
- Thermal Balloon Ablators
- Radiofrequency Endometrial Ablation Devices
- Hydrothermal Ablators
- Electrical Ablators
- Cryoablation Systems
- Microwave Ablation Probes
- By Access Approach
- Hysteroscopic Systems
- Transcervical Non-hysteroscopic (RF, Balloons)
- Image-Guided Extra-uterine (MRI-/US-guided HIFU)
- By End-User
- Hospitals
- Ambulatory Surgical Centers
- Specialty Clinics
- Office-based Gynecology Practices
- Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Data Sources, Market Sizing, and Validation
Desk Research
Desk research starts by mapping demand drivers and then building the supply view, with consistent medical and regulatory language across geographies. We referenced public sources such as the US CDC and NIH publications for gynecology health indicators, and the WHO for broader women health burden signals that support procedure demand.
To keep the model tied to adoption patterns, we also used US FDA device databases for clearance status and product labeling cues, and OECD health statistics to track shifts in procedure setting over time. Company annual reports, investor presentations, and reputable press were reviewed to infer product focus and geographic exposure, and patent databases were checked to understand likely technology direction. For cross-checking company scale and recent developments, analysts also used paid subscriptions focused on company financials and intelligence, plus news and financial statements. This list is not exhaustive, and additional public and paid sources were used for data collection, validation, and clarification.
Primary Interviews and Surveys
Primary interviews and surveys were used to test the practical scope and pricing assumptions, especially across office-based care, hospital outpatient, and ASC settings. We spoke with a mix of device-side and care-delivery respondents, then validated the adoption curve across Americas, EMEA, and APAC so regional practice patterns were not averaged out.
Distribution of primary research fieldwork respondents
| Company type | Respondent position | Region |
|---|---|---|
| Top tier: 28% | CXOs: 14% | APAC: 44% |
| Mid tier: 58% | Functional/Unit leaders: 33% | EMEA: 36% |
| Smaller Players: 14% | Managers: 53% | Americas: 20% |
Market-Sizing & Forecasting
The core sizing approach uses a top-down build that reconstructs the treated demand pool from abnormal uterine bleeding prevalence signals, care-seeking behavior, and the share of eligible patients shifting to minimally invasive ablation. Those demand pools are then converted into device revenues using average devices per procedure, replacement and reusable cycle assumptions, and typical price bands by care setting.
To keep totals realistic, we corroborate results with selective bottom-up approximations, such as rolling up revenue from a sampled set of suppliers, checking channel feedback on unit volumes, and validating typical ASP movement over time. Inputs that tend to move the model the most include office-based procedure penetration, hysterectomy substitution trends, reimbursement and coding stability, device mix by energy platform, and regional adoption timing for new indications or labeling updates. Where company-level detail is incomplete, gaps are handled using peer proxies within the same device class, then rechecked against regional demand signals.
For forecasting, we use scenario analysis supported by a simple multivariate regression view, treating procedure pool growth and setting shift as the main drivers and applying price erosion cautiously. Final growth rates are then aligned to what primary respondents indicate through order patterns and capacity planning.
Data Validation & Update Cycle
Outputs are checked against multiple independent signals, including procedure setting trends, clearance activity, and implied unit volumes after applying the defined price ranges. If an assumption creates an abnormal jump in a region or device class, it is flagged, reworked, and reviewed again before sign-off.
Each report goes through a multi-step analyst review so the math, units, and definitions remain consistent across chapters. The model is refreshed annually, and interim updates are triggered when material events occur, such as major labeling changes, reimbursement shifts, or a meaningful change in procedure setting mix. Before delivery, a final pass is completed so clients receive the latest updated view.
Mordor Intelligence's Endometrial Ablation Devices Market Size Compared Against Other Published Estimates
Published market sizes for endometrial ablation devices do not always match because the included revenue items, year selection, and pricing logic differ across publishers. In practice, much of the spread comes from whether procedure-related services are included, how reusable components are treated, and how quickly price declines are applied.
Some external estimates are broad and may mix device revenue with procedure and facility components, or they may assume a single global ASP path that does not reflect office-based adoption. In Mordor Intelligence sizing, only cleared endometrial ablation device systems and procedure-enabling components are counted, and general electrosurgical tools that are not labeled for endometrial ablation are excluded so the total stays tied to the true device demand pool.
Benchmark comparison
| Source | Market Size | Gaps in Research Methodology |
|---|---|---|
| Mordor Intelligence | USD 1.20 B (2025) | |
| Global Research Publisher A | USD 1.32 B (2025) | Uses a different base year and applies higher near-term pricing, and the scope can be interpreted to include a wider set of ablation related offerings beyond device systems and their direct components. |
| Global Research Publisher B | USD 1.25 B (2024) | Reported for a different year and growth window, and the product taxonomy may bundle categories differently, which can shift totals when regional mix and office setting uptake are not modeled separately. |
Taken together, the table shows that year alignment and scope handling explain most of the variance, more than any single growth assumption. By keeping inputs traceable to procedure pool signals and realistic price bands by care setting, we produce a market size that is easier to reproduce and update consistently.
Key Questions Answered in the Report
What is driving the current growth of the endometrial ablation devices market?
Rising abnormal uterine bleeding prevalence, expanding reimbursement for office-based procedures, and AI-guided imaging that improves accuracy are key growth catalysts.
Which device technology is growing fastest through 2031?
Non-thermal systems—such as cryoablation and laser platforms—are expected to expand at a 9.12% CAGR, outpacing thermal modalities.
Why are ambulatory surgical centers important for future market uptake?
ASCs offer cost savings near USD 1,500 per case, shorter recovery times, and high patient satisfaction, making them the fastest-growing end-user segment at a 10.05% CAGR.
How are regulations affecting product launch timelines?
Divergent global rules and new FDA thermal-effect guidance increase data requirements, extending approval timelines and raising compliance costs, especially for novel platforms.
Which geographic region will contribute most to additional revenue by 2031?
Asia-Pacific, forecast to grow at an 8.10% CAGR, will add the greatest share of incremental revenue as healthcare access and disposable incomes rise.
Page last updated on:
